2019冠状病毒病的治疗：对非洲抗菌药物耐药性的影响
Treatment of COVID-19: implications for antimicrobial resistance in Africa.
作者信息
Iwu Chinwe Juliana, Jordan Portia, Jaja Ishmael Festus, Iwu Chidozie Declan, Wiysonge Charles Shey
机构信息
Department of Nursing and Midwifery, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Department of Livestock and Pasture Sciences, Faculty of Science and Agriculture, University of Fort Hare, Alice 5700, South Africa.
出版信息
Pan Afr Med J. 2020 Jul 20;35(Suppl 2):119. doi: 10.11604/pamj.supp.2020.35.23713. eCollection 2020.
Abstract
There is currently no approved pharmaceutical product for the treatment of COVID-19. However, antibiotics are currently being used for the management of COVID-19 patients in many settings either treat to co-infections or for the treatment of COVID-19 itself. In this commentary, we highlight that the increased rates of antimicrobial prescribing for COVID-19 patients could further worsen the burden of antimicrobial resistance (AMR). We also highlight that though AMR is a global threat, Africa tends to suffer most from the consequences. We, therefore, call on African countries not to lose sight of the possible implications of the treatment of COVID-19 on AMR and a need to redouble efforts towards the fight against AMR while dealing with the pandemic.
摘要
目前尚无获批用于治疗新冠肺炎的药物产品。然而，目前在许多情况下，抗生素正被用于新冠肺炎患者的治疗，要么用于治疗合并感染，要么用于治疗新冠肺炎本身。在本评论中，我们强调，新冠肺炎患者抗菌药物处方率的上升可能会进一步加重抗菌药物耐药性（AMR）的负担。我们还强调，尽管抗菌药物耐药性是一个全球性威胁，但非洲往往受其影响最为严重。因此，我们呼吁非洲国家不要忽视治疗新冠肺炎对抗菌药物耐药性可能产生的影响，以及在应对疫情的同时需要加倍努力抗击抗菌药物耐药性。
相似文献
1
Treatment of COVID-19: implications for antimicrobial resistance in Africa.2019冠状病毒病的治疗：对非洲抗菌药物耐药性的影响
Pan Afr Med J. 2020 Jul 20;35(Suppl 2):119. doi: 10.11604/pamj.supp.2020.35.23713. eCollection 2020.
2
Antimicrobial resistance and COVID-19: Intersections and implications.抗微生物药物耐药性与 COVID-19：交叉与影响。
Elife. 2021 Feb 16;10:e64139. doi: 10.7554/eLife.64139.
3
Antimicrobial Resistance in the COVID-19 Landscape: Is There an Opportunity for Anti-Infective Antibodies and Antimicrobial Peptides?新型冠状病毒肺炎疫情下的抗菌药物耐药性：抗感染抗体和抗菌肽是否有机会？
Front Immunol. 2022 Jun 2;13:921483. doi: 10.3389/fimmu.2022.921483. eCollection 2022.
4
Coronavirus Disease 2019 and Antimicrobial Resistance: Parallel and Interacting Health Emergencies.2019 年冠状病毒病与抗菌药物耐药性：平行且相互作用的健康紧急事件。
Clin Infect Dis. 2021 May 4;72(9):1657-1659. doi: 10.1093/cid/ciaa773.
5
Nanobiotics against antimicrobial resistance: harnessing the power of nanoscale materials and technologies.纳米生物技术对抗抗菌药物耐药性：利用纳米尺度材料和技术的力量。
J Nanobiotechnology. 2022 Aug 12;20(1):375. doi: 10.1186/s12951-022-01573-9.
6
COVID-19: Clouds Over the Antimicrobial Resistance Landscape.COVID-19：抗生素耐药性领域的阴云。
Arch Med Res. 2021 Jan;52(1):123-126. doi: 10.1016/j.arcmed.2020.10.010. Epub 2020 Oct 10.
7
Antimicrobial resistance research in a post-pandemic world: Insights on antimicrobial resistance research in the COVID-19 pandemic.大流行后世界的抗菌药物耐药性研究：关于新冠疫情中抗菌药物耐药性研究的见解
J Glob Antimicrob Resist. 2021 Jun;25:5-7. doi: 10.1016/j.jgar.2021.02.013. Epub 2021 Mar 1.
8
Impact of the COVID-19 pandemic on the surveillance, prevention and control of antimicrobial resistance: a global survey.新冠疫情对抗菌药物耐药性监测、预防和控制的影响：全球调查。
J Antimicrob Chemother. 2021 Oct 11;76(11):3045-3058. doi: 10.1093/jac/dkab300.
9
How can lessons from the COVID-19 pandemic enhance antimicrobial resistance surveillance and stewardship?从 COVID-19 大流行中吸取的教训如何增强抗菌药物耐药性监测和管理？
Lancet Infect Dis. 2023 Aug;23(8):e301-e309. doi: 10.1016/S1473-3099(23)00124-X. Epub 2023 Jun 5.
10
Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance.关于 COVID-19 大流行对抗菌药物耐药性研究和监测的潜在影响的关键考虑因素。
Trans R Soc Trop Med Hyg. 2021 Oct 1;115(10):1122-1129. doi: 10.1093/trstmh/trab048.
引用本文的文献
1
Impact of a hub-and-spoke approach to hospital antimicrobial stewardship programmes on antibiotic use in Zambia.中心辐射型医院抗菌药物管理计划对赞比亚抗生素使用的影响。
JAC Antimicrob Resist. 2024 Nov 5;6(6):dlae178. doi: 10.1093/jacamr/dlae178. eCollection 2024 Dec.
2
Surveillance of antimicrobial resistance in human health in Tanzania: 2016-2021.坦桑尼亚2016 - 2021年人类健康领域抗菌药物耐药性监测
Afr J Lab Med. 2023 May 22;12(1):2053. doi: 10.4102/ajlm.v12i1.2053. eCollection 2023.
3
Antibiotic Overprescribing among Neonates and Children Hospitalized with COVID-19 in Pakistan and the Implications.巴基斯坦新冠肺炎住院新生儿和儿童的抗生素过度处方及其影响
Antibiotics (Basel). 2023 Mar 24;12(4):646. doi: 10.3390/antibiotics12040646.
4
Ongoing Efforts to Improve Antimicrobial Utilization in Hospitals among African Countries and Implications for the Future.非洲国家为改善医院抗菌药物使用情况所做的持续努力及其对未来的影响。
Antibiotics (Basel). 2022 Dec 15;11(12):1824. doi: 10.3390/antibiotics11121824.
5
Multidrug resistant bacterial infections in severely ill COVID-19 patients admitted in a national referral and teaching hospital, Kenya.肯尼亚一家国家转诊和教学医院收治的重症 COVID-19 患者中的耐多药细菌感染。
BMC Infect Dis. 2022 Nov 22;22(1):877. doi: 10.1186/s12879-022-07885-3.
6
Coronavirus Disease 2019 (COVID-19) Pandemic across Africa: Current Status of Vaccinations and Implications for the Future.2019年冠状病毒病（COVID-19）在非洲的大流行：疫苗接种现状及对未来的影响。
Vaccines (Basel). 2022 Sep 17;10(9):1553. doi: 10.3390/vaccines10091553.
7
COVID-19 and the rising scourge of antimicrobial resistance: A perspective from Pakistan.2019冠状病毒病与日益严重的抗菌药物耐药性问题：来自巴基斯坦的视角
Ann Med Surg (Lond). 2022 Aug;80:104262. doi: 10.1016/j.amsu.2022.104262. Epub 2022 Jul 31.
8
Prevalence of bacterial coinfection and patterns of antibiotics prescribing in patients with COVID-19: A systematic review and meta-analysis.新冠病毒感染患者的细菌合并感染率和抗生素使用模式：系统评价和荟萃分析。
PLoS One. 2022 Aug 1;17(8):e0272375. doi: 10.1371/journal.pone.0272375. eCollection 2022.
9
Empiric Antibiotics in COVID 19: A Narrative Review.新型冠状病毒肺炎的经验性抗生素治疗：一项叙述性综述
Cureus. 2022 Jun 2;14(6):e25596. doi: 10.7759/cureus.25596. eCollection 2022 Jun.
10
Cropping Up Crisis at the Nexus Between COVID-19 and Antimicrobial Resistance (AMR) in Africa: A Scoping Review and Synthesis of Early Evidence.非洲新冠疫情与抗菌药物耐药性（AMR）交叉点上出现的危机：一项早期证据的范围审查与综合分析
Cureus. 2022 Jan 8;14(1):e21035. doi: 10.7759/cureus.21035. eCollection 2022 Jan.
本文引用的文献
1
Tackling antimicrobial resistance in the COVID-19 pandemic.应对新冠疫情中的抗菌药物耐药性问题。
Bull World Health Organ. 2020 Jul 1;98(7):442-442A. doi: 10.2471/BLT.20.268573.
2
Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing.细菌和真菌合并感染冠状病毒的个体：一项支持 COVID-19 抗菌药物处方的快速综述。
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468. doi: 10.1093/cid/ciaa530.
3
Implementation of antimicrobial stewardship programmes in African countries: a systematic literature review.非洲国家抗菌药物管理计划的实施：系统文献回顾。
J Glob Antimicrob Resist. 2020 Sep;22:317-324. doi: 10.1016/j.jgar.2020.03.009. Epub 2020 Apr 1.
4
Antimicrobial resistance: a global public health emergency further exacerbated by international travel.抗微生物药物耐药性：一场因国际旅行而进一步加剧的全球公共卫生紧急事件。
J Travel Med. 2020 Feb 3;27(1). doi: 10.1093/jtm/taz095.
5
Antimicrobial resistance from a one health perspective in Cameroon: a systematic review and meta-analysis.从“同一健康”角度看喀麦隆的抗菌药物耐药性：系统评价和荟萃分析。
BMC Public Health. 2019 Aug 19;19(1):1135. doi: 10.1186/s12889-019-7450-5.
6
Africa Centres for Disease Control and Prevention's framework for antimicrobial resistance control in Africa.非洲疾病控制与预防中心的非洲抗菌药物耐药性控制框架。
Afr J Lab Med. 2018 Dec 6;7(2):830. doi: 10.4102/ajlm.v7i2.830. eCollection 2018.
7
Global increase and geographic convergence in antibiotic consumption between 2000 and 2015.2000 年至 2015 年间，抗生素消费在全球范围内增长，并在地理上趋同。
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3463-E3470. doi: 10.1073/pnas.1717295115. Epub 2018 Mar 26.
8
Interventions to improve antibiotic prescribing practices for hospital inpatients.改善医院住院患者抗生素处方行为的干预措施。
Cochrane Database Syst Rev. 2017 Feb 9;2(2):CD003543. doi: 10.1002/14651858.CD003543.pub4.
9
Antimicrobial resistance in the WHO African region: current status and roadmap for action.世界卫生组织非洲区域的抗菌素耐药性：现状与行动路线图
J Public Health (Oxf). 2017 Mar 1;39(1):8-13. doi: 10.1093/pubmed/fdw015.
Zotero 插件